M&A and IPOs by Dan Primack @FortuneMagazine May 28, 2013, 2:09 PM EDT E-mail Tweet Facebook Google Plus Linkedin Share icons Valeant Pharmaceuticals (NYSE: VRX) has agreed to acquire eye-care company Bausch & Lomb Inc. from Warburg Pincus for $8.7 billion in cash. Approximately $4.5 billion of the proceeds will go to B&L shareholders like Warburg Pincus, while the remaining $4.2 billion will be used to repay existing indebtedness. Warburg Pincus acquired B&L in late 2007 for $4.5 billion (including debt). It had been running a parallel IPO process for the company, which reported $65.4 million net loss on $1.29 billion in revenue for 2012. www.bausch.com AstraZeneca PLC (LSE: AZN) has agreed to acquire Omthera Pharmaceuticals Inc. (Nasdaq: OMTH), a Bedminster, N.J.-based drug company focused on dyslipidemia, for approximately $323 million (including $63 million of cash on hand). The $12.70 per share deal represents around an 88% premium to Friday’s closing price, and there also is an additional $4.70 per share in earnout possibilities (via contingent value rights) that works out to a total of $120 million. www.omthera.com AXA Private Equity is considering a sale of French food company Diana Ingredients, according to Private Equity International. AXA bought Diana back in 2007 for €710 million from Cognetas, and now would be expecting north of €1 billion. Deutsche Telekom is in talks to acquire Polish broadband company GTS Central Europe for approximately €600 million, according to the WSJ. GTS shareholders include Columbia Capital, Bessemer Venture Partners, M/C Venture Partners, Innova Capital, HarbourVest Partners and Oak Investment Partners. The report adds that Deutsche Telekom “could also come under pressure to purchase the outstanding 40% stake of its T-Mobile Czech Republic unit that was recently put up for sale by private-equity firm Mid Europa Partners.” Teco Energy Inc. (NYSE: TE) has agreed to acquire New Mexico Gas Co. from Continental Energy Systems, a portfolio company of Lindsay Goldberg LLC. The deal is valued at approximately $950 million (including assumed debt). www.nmgco.com Azul Linhas Aereas Brasileiras, a Brazilian airline, has filed for a $100 million IPO. It plans to trade on the NYSE and in Brazil, with Morgan Stanley serving as lead underwriter. Shareholders include Weston Presidio (13.1% pre-IPO stake), TPG Growth (9%) and Gávea Group (7.8%). Coty Inc., a New York-based maker of beauty products, has set its IPO terms to around 57.14 million shares being offered at between $16.50 and $18.50 per share. It plans to trade on the NYSE under ticker symbol COTY, with BoA Merrill Lynch, J.P. Morgan and Morgan Stanley leading an underwriting group that also includes 17 other banks. Coty reports $89.9 million in net income on over $4 billion in revenue for fiscal 2011, which ended last June 30. Berkshire Partners and Rhone Capital each hold a 7.5% ownership stake. Coty had offered to buy Avon for around $10 billion earlier this year, but was rebuffed. www.coty.com Evoke Pharma Inc., a San Diego-based drug developer focused on gastrointestinal disorders, has filed for a $23 million IPO. It plans to trade on the Nasdaq under ticker symbol EVOK, with Aegis Capital Corp. serving as lead underwriter. Shareholders include Domain Associates (30.9%), Latterell Venture Partners (30.9%) and WIndamere Venture Partners. www.evokepharma.com Prosensa Holding BV, a Dutch, developer of RNA-modulating therapeutics for the treatment of genetic disorders, has filed for a $60 million IPO. It plans to trade on the Nasdaq under ticker symbol RNA, with J.P. Morgan and Citigroup serving as lead underwriters. Shareholders include Abingworth Management (21.43% pre-IPO stake), Life Sciences Partners (21.43%), New Enterprise Associates (20.75%), GIMV (9.03%), Idinvest Partners (9.03%) and MedSciences Capital (6.88%). www.prosensa.com Regado Biosciences Inc., a Basking Ridge, N.J.-based developer of antithrombotic drug systems for acute and sub-acute cardiovascular indications, has set its IPO terms to 5 million common shares being offered at between $14 and $16 per share. The company would have an initial market cap of around $215 million, were it to price in the middle of its range. Regardo plans to trade on the Nasdaq under ticker symbol RGDO, with Cowan & Co. and BMO Capital Markets serving as lead underwriters. Shareholders in the pre-revenue company include Domain Associates (19.2% pre-IPO stake), Quaker BioVentures (12.7%), Edmond de Rothschild Investment Partners (12.4%), RMI Investments (14.2%) and The Aurora Funds (7.9%). www.regadobio.com WCI Communities Inc., a Bonita Springs, Fla.-based luxury homebuilder in coastal Florida, has filed for a $150 million IPO. It plans to trade on the NYSE under ticker symbol WCIC, with Citigroup, Credit Suisse and J.P. Morgan serving as lead underwriters. Shareholders include Monarch Alternative Capital (40.1% pre-IPO stake), Stonehill Institutional Partners (36.1%) and Royal Bank of Scotland (5.9%). www.wcicommunities.com Two companies are expected to price IPOs this week: Epizyme, a Cambridge, Mass.-based biopharma company focused on the application of epigenetics; and Kamada, an Israeli provider of plasma-derived protein therapeutics.